Trial intelligence / Profile preview

Natalizumab in adolescents with Crohn's disease

NCT00055367Phase 2Completed

Sponsor
Biogen
Start
Apr 2002
Primary completion
May 2004
Modality
Monoclonal Antibodies
Countries
2
01

Overview

A Phase 2 trial of natalizumab in Crohn's disease, sponsored by Biogen. Started Apr 2002; status: completed.

02

Drugs

natalizumab
03

Conditions

Crohn's disease

Beyond the preview

Go deeper on NCT00055367.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT00055367.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call